TD SYNNEX’s BlueStar deal has no disclosed price. Its $1.33 billion quarterly profit-to-cash gap makes funding and working ...
Pfizer’s new Tukysa FDA approval follows an 11% U.S. sales decline in Q2. What the label changes, its 0.9% revenue share and the November 3 earnings checkpoint.
Musk’s Terafab clarification puts Intel and TSMC stock in focus. Compare confirmed roles, foundry revenue, Q2 margins and the ...
AMD stock faces a key November earnings test as AI demand, data-center growth, margins and supply execution shape the next ...
CEG stock jumped 12% after Google’s nuclear agreement. TECHi tests the $4.3 billion investment, missing power price and ...
CIEN stock surged 11% Tuesday. TECHi tests Ciena’s 2029 revenue, margin and cash-flow targets against its October 6 valuation ...
ALAB stock climbed nearly 7% Tuesday. TECHi explains the Scorpio revenue ramp, OCP catalyst and valuation risk behind Astera ...
CBRS closed up 9.08% after OpenAI reassurance. Cerebras's Q3 core-revenue guide implies 2.4% sequential growth; delivery ...
Mean analyst target$799,502.75Analyst target periodDefinition & source ↗Yahoo Finance Median analyst target$778,500Analyst target periodDefinition & source ↗Yahoo Finance Lowest analyst ...
APP closed up 5.13% on October 5 after nine losses. The Unity dispute remains open, and AppLovin’s $2.055 billion Q3 sales ...
The $205-a-share offer gives PTC holders a proposed cash exit. Schneider’s valuation case depends on projected cross-selling, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results